DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer

Phase 3

Completed

Conditions: Stage III Esophageal Squamous Cell Carcinoma

Interventions: Drug: Paclitaxel and Fluorouracil
Drug: Paclitaxel and Carboplatin
Drug: Paclitaxel and Cisplatin
Radiation: Radiotherapy

First Posted Date: 2015-06-02

Last Posted Date: 2022-02-09

Lead Sponsor: Fudan University

Target Recruit Count: 321

Registration Number: NCT02459457

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients

Phase 2

Conditions: Colorectal Cancer

Interventions: Drug: capecitabine plus oxaliplatin

First Posted Date: 2015-04-14

Last Posted Date: 2015-04-14

Lead Sponsor: Fudan University

Target Recruit Count: 55

Registration Number: NCT02415829

Locations: 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China

The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Oxaliplatin
Drug: Epirubicin
Drug: Capecitabine

First Posted Date: 2015-03-23

Last Posted Date: 2021-10-26

Lead Sponsor: Fudan University

Target Recruit Count: 438

Registration Number: NCT02395640

Locations: 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China

Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Radiation: radiation

First Posted Date: 2015-03-10

Last Posted Date: 2017-09-07

Lead Sponsor: Fudan University

Target Recruit Count: 70

Registration Number: NCT02384811

Locations: 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients

Phase 2

Conditions: Colorectal Carcinoma

Interventions: Drug: Raltitrexed
Drug: Irinotecan
Drug: 5-fluorouracil
Drug: Leucovorin

First Posted Date: 2015-03-03

Last Posted Date: 2015-03-03

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT02376452

Locations: 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China

Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Bicalutamide

First Posted Date: 2015-01-28

Last Posted Date: 2018-01-23

Lead Sponsor: Fudan University

Target Recruit Count: 1

Registration Number: NCT02348281

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine,cisplatin
Drug: Gemcitabine,carboplatin

First Posted Date: 2015-01-19

Last Posted Date: 2022-04-20

Lead Sponsor: Fudan University

Target Recruit Count: 150

Registration Number: NCT02341911

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Aprepitant
Drug: Mirtazapine

First Posted Date: 2015-01-13

Last Posted Date: 2022-04-20

Lead Sponsor: Fudan University

Target Recruit Count: 212

Registration Number: NCT02336750

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, China

Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Non-alcoholic Fatty Liver Disease

Interventions: Drug: Exenatide
Drug: insulin glargine

First Posted Date: 2014-12-01

Last Posted Date: 2019-08-28

Lead Sponsor: Fudan University

Target Recruit Count: 76

Registration Number: NCT02303730

Locations: 🇨🇳
Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳
Department of Endocrinology and Metabolism, Shanghai Minhang Central Hospital, Shanghai, Shanghai, China
🇨🇳
Department of Endocrinology and Metabolism,Huadong Hospital, Shanghai, Shanghai, China

and more 2 locations

Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial

Phase 3

Completed

Conditions: Kawasaki Disease

Interventions: Drug: Infliximab
Drug: IVIG

First Posted Date: 2014-11-21

Last Posted Date: 2016-02-03

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT02298062

Locations: 🇨🇳
Children Hospital of Fudan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy